Cargando…

Pirarubicin Combination Low-Dose Chemotherapy for Early Infantile Stage MS Neuroblastoma: Case Report

Neuroblastoma (NB) is a neural crest-derived malignant tumor which is diagnosed during infancy in approximately 40% of cases; spontaneous regressions are observed, but there are varying degrees of severity. Treatment is indicated if an infant’s condition is at risk of deterioration. Herein, we repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Yutaka, Kawaguchi, Hiroshi, Sakata, Naoki, Ueda, Satoshi, Okano, Munehiro, Nishino, Yuuki, Ryujin, Masako, Takemura, Yutaka, Takemura, Tsukasa, Sugimoto, Keisuke, Okada, Satoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217743/
https://www.ncbi.nlm.nih.gov/pubmed/37238419
http://dx.doi.org/10.3390/children10050871
_version_ 1785048611230318592
author Kato, Yutaka
Kawaguchi, Hiroshi
Sakata, Naoki
Ueda, Satoshi
Okano, Munehiro
Nishino, Yuuki
Ryujin, Masako
Takemura, Yutaka
Takemura, Tsukasa
Sugimoto, Keisuke
Okada, Satoshi
author_facet Kato, Yutaka
Kawaguchi, Hiroshi
Sakata, Naoki
Ueda, Satoshi
Okano, Munehiro
Nishino, Yuuki
Ryujin, Masako
Takemura, Yutaka
Takemura, Tsukasa
Sugimoto, Keisuke
Okada, Satoshi
author_sort Kato, Yutaka
collection PubMed
description Neuroblastoma (NB) is a neural crest-derived malignant tumor which is diagnosed during infancy in approximately 40% of cases; spontaneous regressions are observed, but there are varying degrees of severity. Treatment is indicated if an infant’s condition is at risk of deterioration. Herein, we report the case of a 42-day-old boy who presented with hepatomegaly and was diagnosed with stage MS NB. A pathological diagnosis of “poorly differentiated neuroblastoma with low mitosis-karyorrhexis index, favorable histology” was made; his tumor cells were hyperdiploid and MYCN was not amplified. Because he had respiratory distress caused by the rapidly evolving hepatomegaly, two cycles of chemotherapy containing vincristine and cyclophosphamide were administered in the second and fourth weeks of admission; however, his abdominal tumor did not shrink. In the sixth week of admission, chemotherapy was revised to pirarubicin and cyclophosphamide, and the tumor began to shrink. After discharge, there was no re-elevation of tumor markers; after 1 year, the hepatomegaly and liver metastases disappeared. During the 5-year follow-up, his growth and development were normal and he progressed without sequelae. A regimen that includes pirarubicin could merit further study in the treatment of early infants with stage MS low-risk NB who are at risk of complications.
format Online
Article
Text
id pubmed-10217743
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102177432023-05-27 Pirarubicin Combination Low-Dose Chemotherapy for Early Infantile Stage MS Neuroblastoma: Case Report Kato, Yutaka Kawaguchi, Hiroshi Sakata, Naoki Ueda, Satoshi Okano, Munehiro Nishino, Yuuki Ryujin, Masako Takemura, Yutaka Takemura, Tsukasa Sugimoto, Keisuke Okada, Satoshi Children (Basel) Case Report Neuroblastoma (NB) is a neural crest-derived malignant tumor which is diagnosed during infancy in approximately 40% of cases; spontaneous regressions are observed, but there are varying degrees of severity. Treatment is indicated if an infant’s condition is at risk of deterioration. Herein, we report the case of a 42-day-old boy who presented with hepatomegaly and was diagnosed with stage MS NB. A pathological diagnosis of “poorly differentiated neuroblastoma with low mitosis-karyorrhexis index, favorable histology” was made; his tumor cells were hyperdiploid and MYCN was not amplified. Because he had respiratory distress caused by the rapidly evolving hepatomegaly, two cycles of chemotherapy containing vincristine and cyclophosphamide were administered in the second and fourth weeks of admission; however, his abdominal tumor did not shrink. In the sixth week of admission, chemotherapy was revised to pirarubicin and cyclophosphamide, and the tumor began to shrink. After discharge, there was no re-elevation of tumor markers; after 1 year, the hepatomegaly and liver metastases disappeared. During the 5-year follow-up, his growth and development were normal and he progressed without sequelae. A regimen that includes pirarubicin could merit further study in the treatment of early infants with stage MS low-risk NB who are at risk of complications. MDPI 2023-05-12 /pmc/articles/PMC10217743/ /pubmed/37238419 http://dx.doi.org/10.3390/children10050871 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Kato, Yutaka
Kawaguchi, Hiroshi
Sakata, Naoki
Ueda, Satoshi
Okano, Munehiro
Nishino, Yuuki
Ryujin, Masako
Takemura, Yutaka
Takemura, Tsukasa
Sugimoto, Keisuke
Okada, Satoshi
Pirarubicin Combination Low-Dose Chemotherapy for Early Infantile Stage MS Neuroblastoma: Case Report
title Pirarubicin Combination Low-Dose Chemotherapy for Early Infantile Stage MS Neuroblastoma: Case Report
title_full Pirarubicin Combination Low-Dose Chemotherapy for Early Infantile Stage MS Neuroblastoma: Case Report
title_fullStr Pirarubicin Combination Low-Dose Chemotherapy for Early Infantile Stage MS Neuroblastoma: Case Report
title_full_unstemmed Pirarubicin Combination Low-Dose Chemotherapy for Early Infantile Stage MS Neuroblastoma: Case Report
title_short Pirarubicin Combination Low-Dose Chemotherapy for Early Infantile Stage MS Neuroblastoma: Case Report
title_sort pirarubicin combination low-dose chemotherapy for early infantile stage ms neuroblastoma: case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217743/
https://www.ncbi.nlm.nih.gov/pubmed/37238419
http://dx.doi.org/10.3390/children10050871
work_keys_str_mv AT katoyutaka pirarubicincombinationlowdosechemotherapyforearlyinfantilestagemsneuroblastomacasereport
AT kawaguchihiroshi pirarubicincombinationlowdosechemotherapyforearlyinfantilestagemsneuroblastomacasereport
AT sakatanaoki pirarubicincombinationlowdosechemotherapyforearlyinfantilestagemsneuroblastomacasereport
AT uedasatoshi pirarubicincombinationlowdosechemotherapyforearlyinfantilestagemsneuroblastomacasereport
AT okanomunehiro pirarubicincombinationlowdosechemotherapyforearlyinfantilestagemsneuroblastomacasereport
AT nishinoyuuki pirarubicincombinationlowdosechemotherapyforearlyinfantilestagemsneuroblastomacasereport
AT ryujinmasako pirarubicincombinationlowdosechemotherapyforearlyinfantilestagemsneuroblastomacasereport
AT takemurayutaka pirarubicincombinationlowdosechemotherapyforearlyinfantilestagemsneuroblastomacasereport
AT takemuratsukasa pirarubicincombinationlowdosechemotherapyforearlyinfantilestagemsneuroblastomacasereport
AT sugimotokeisuke pirarubicincombinationlowdosechemotherapyforearlyinfantilestagemsneuroblastomacasereport
AT okadasatoshi pirarubicincombinationlowdosechemotherapyforearlyinfantilestagemsneuroblastomacasereport